John Clarke

UA researchers link liver disease, drug metabolism

Researchers at the University of Arizona College of Pharmacy have discovered that nonalcoholic steatohepatitis (NASH), an increasingly common but often undiagnosed liver disease, could have significant medical implications for people with type 2 diabetes. John Clarke, PhD, research associate, and Nathan Cherrington, PhD, professor, both of the college’s Department of Pharmacology and Toxicology, recently published a study in the journal Diabetes showing that a mouse model of obesity, diabetes and NASH retaine

John Clark in the Pharmacy Spotlight

John Clarke, PhD, research associate in the College of Pharmacy Department of Pharmacology and Toxicology, received a 2015 Best Postdoctoral Publication Award from the Postdoctoral Assembly Executive Board of the Society of Toxicology for his paper “Synergistic Interaction between Genetics and Disease on Pravastatin Disposition.” Clarke will receive $250 and a plaque commemorating this award, which recognizes talented postdoctoral researchers who have recently published papers in the field of

Interaction Between the Liver Disease Nonalcoholic Steatohepatitis and the Ubiquitous Cyanotoxin Microcystin-LR Found in Drinking Water Around the World

Dr. John Clarke received SWEHSC pilot project and career development funds to collect preliminary data for his K99/R00 application to the NIEHS and to facilitate professional development activities. MCLR exposure is well documented to cause hepatic and renal toxicities. The overlap between this at-risk population (NASH patients) and MCLR exposure is anticipated to impact millions of people worldwide because of the current and increasing incidence of NASH and cyanotoxin producing blooms.

Subscribe to RSS - John Clarke